{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T11:52:18Z","timestamp":1785498738040,"version":"3.56.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T00:00:00Z","timestamp":1716940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T00:00:00Z","timestamp":1716940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Assist Reprod Genet"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To investigate whether the ovarian stimulation with follitropin delta in an individualized algorithm-based manner is inferior to recombinant human-follicle stimulating\u2019s follitropin alfa or follitropin beta conventional dosing regarding a series of established primary endpoints.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a registered systematic review (CRD42024512792) on PubMed-MEDLINE, Web of Science\u2122, Cochrane Database of Systematic Reviews, and Scopus. Our search was designed to cover all relevant literature, particularly randomized controlled trials. We critically and comparatively analyzed the outcomes for each primary endpoint based on the intervention, reflected by the positive \u03b2hCG test, clinical pregnancy, vital pregnancy, ongoing pregnancy, live birth, live birth at 4 weeks, and multiple pregnancies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Six randomized controlled trials were included in the quality assessment as priority manuscripts, revealing an 83.3% low risk of bias. Follitropin delta led to non-significant differences in each parameter of interest from positive \u03b2hCG test (691; 53.44% vs. 602; 46.55%), ongoing pregnancies (603; 53.79% vs. 518; 46.20%), clinical and vital pregnancies (1,073; 52.80% vs. 959; 47.19%), to live birth and at 4 weeks (595; 54.14% vs. 504; 45.85%) with only 2 losses, and even multiple pregnancies (8; 66.66% vs. 4; 33.33%). However, follitropin delta was well-tolerated among hypo- and hyper-responders without significant risk of ovarian hyperstimulation syndrome and\/or preventive interventions in contrast with follitropin alfa or follitropin beta.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The personalized individualized-based algorithm dosing with follitropin delta is non-inferior to conventional follitropin alfa or follitropin beta. It is as effective in promoting a similar response in women without significant comparable adverse effects.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10815-024-03146-1","type":"journal-article","created":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T07:02:18Z","timestamp":1716966138000},"page":"1851-1861","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The pregnancy outcomes among women receiving individualized algorithm dosing with follitropin delta: a systematic review of randomized controlled trials"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6618-141X","authenticated-orcid":false,"given":"Bogdan","family":"Doroftei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4023-1765","authenticated-orcid":false,"given":"Ovidiu-Dumitru","family":"Ilie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana-Maria","family":"Dabuleanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodora","family":"Armeanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radu","family":"Maftei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,29]]},"reference":[{"key":"3146_CR1","doi-asserted-by":"publisher","first-page":"429","DOI":"10.3389\/fendo.2019.00429","volume":"10","author":"B Lunenfeld","year":"2019","unstructured":"Lunenfeld B, Bilger W, Longobardi S, Alam V, D\u2019Hooghe T, Sunkara SK. The Development of Gonadotropins for Clinical Use in the Treatment of Infertility [Internet]. Front Endocrinol. 2019;10:429. https:\/\/doi.org\/10.3389\/fendo.2019.00429.","journal-title":"Front Endocrinol"},{"key":"3146_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s12522-011-0097-2","volume":"11","author":"B Lunenfeld","year":"2012","unstructured":"Lunenfeld B. Gonadotropin stimulation: past, present and future. Reprod Med Biol [Internet]. 2012;11:11\u201325. https:\/\/doi.org\/10.1007\/s12522-011-0097-2.","journal-title":"Reprod Med Biol [Internet]"},{"key":"3146_CR3","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.fertnstert.2018.06.005","volume":"110","author":"C Niederberger","year":"2018","unstructured":"Niederberger C, Pellicer A, Cohen J, Gardner DK, Palermo GD, O\u2019Neill CL, et al. Forty years of IVF. Fertil Steril [Internet]. 2018;110:185-324.e5. https:\/\/doi.org\/10.1016\/j.fertnstert.2018.06.005.","journal-title":"Fertil Steril [Internet]"},{"key":"3146_CR4","doi-asserted-by":"publisher","first-page":"636038","DOI":"10.3389\/fendo.2021.636038","volume":"12","author":"J Dias","year":"2021","unstructured":"Dias J, Ulloa-Aguirre A. New human follitropin preparations: how glycan structural differences may affect biochemical and biological function and clinical effect. Front Endocrinol (Lausanne). 2021;12:636038.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"3146_CR5","doi-asserted-by":"crossref","unstructured":"De Leo V, Musacchio MC, Di Sabatino A, Tosti C, Morgante G, Petraglia F. Present and future of recombinant gonadotropins in reproductive medicine [Internet]. Curr Pharm Biotechnol. 2012;13(3):379\u201391. http:\/\/www.eurekaselect.com\/node\/76486\/article. Accessed 1 Mar 2024.","DOI":"10.2174\/138920112799361918"},{"key":"3146_CR6","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/S0015-0282(00)00524-0","volume":"73","author":"FI Sharara","year":"2000","unstructured":"Sharara FI, McClamrock HD. Differences in in vitro fertilization (IVF) outcome between white and black women in an inner-city, university-based IVF program. Fertil Steril. 2000;73:1170\u20133.","journal-title":"Fertil Steril"},{"key":"3146_CR7","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.fertnstert.2006.06.031","volume":"87","author":"K Purcell","year":"2007","unstructured":"Purcell K, Schembri M, Frazier LM, Rall MJ, Shen S, Croughan M, et al. Asian ethnicity is associated with reduced pregnancy outcomes after assisted reproductive technology. Fertil Steril. 2007;87:297\u2013302.","journal-title":"Fertil Steril"},{"key":"3146_CR8","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/j.fertnstert.2009.11.019","volume":"94","author":"HG Huddleston","year":"2010","unstructured":"Huddleston HG, Rosen MP, Lamb JD, Modan A, Cedars MI, Fujimoto VY. Asian ethnicity in anonymous oocyte donors is associated with increased estradiol levels but comparable recipient pregnancy rates compared with Caucasians. Fertil Steril. 2010;94:2059\u201363.","journal-title":"Fertil Steril"},{"key":"3146_CR9","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s10815-017-1071-7","volume":"35","author":"AM Tabbalat","year":"2018","unstructured":"Tabbalat AM, Pereira N, Klauck D, Melhem C, Elias RT, Rosenwaks Z. Arabian Peninsula ethnicity is associated with lower ovarian reserve and ovarian response in women undergoing fresh ICSI cycles. J Assist Reprod Genet. 2018;35:331\u20137.","journal-title":"J Assist Reprod Genet"},{"key":"3146_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/humupd\/dmm034","volume":"14","author":"BCJM Fauser","year":"2008","unstructured":"Fauser BCJM, Diedrich K, Devroey P. Predictors of ovarian response: progress towards individualized treatment in ovulation induction and ovarian stimulation. Hum Reprod Update. 2008;14:1\u201314.","journal-title":"Hum Reprod Update"},{"key":"3146_CR11","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.fertnstert.2012.11.051","volume":"99","author":"SM Nelson","year":"2013","unstructured":"Nelson SM. Biomarkers of ovarian response: current and future applications. Fertil Steril [Internet]. 2013;99:963\u20139. https:\/\/doi.org\/10.1016\/j.fertnstert.2012.11.051.","journal-title":"Fertil Steril [Internet]"},{"key":"3146_CR12","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1093\/humupd\/dmt037","volume":"20","author":"A La Marca","year":"2014","unstructured":"La Marca A, Sunkara SK. Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice. Hum Reprod Update [Internet]. 2014;20:124\u201340. https:\/\/doi.org\/10.1093\/humupd\/dmt037.","journal-title":"Hum Reprod Update [Internet]"},{"key":"3146_CR13","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1093\/humupd\/dml034","volume":"12","author":"FJ Broekmans","year":"2006","unstructured":"Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update. 2006;12:685\u2013718.","journal-title":"Hum Reprod Update"},{"key":"3146_CR14","unstructured":"ESHRE Guidelines. Ovarian stimulation for IVF\/ICSI. In: Guideline of the European society of human reproduction and embryology (2019) [Internet]. 2019. https:\/\/www.google.com\/search?q=.+Available+at%3A+https%3A%2F%2F+www.Eshre.Eu%2F-%2FMedia%2FSitecore-Files%2FGuidelines%2FCos%2FEshre-Cos-Guideline_Final%0209102019_.Pdf%3FLa%3DEn%26Hash%3D2316ea35f8afd21c2fb193c33f3bdc272334c901&oq=.+Available+at%3A+http. Accessed 4 Mar 2024."},{"key":"3146_CR15","doi-asserted-by":"crossref","unstructured":"Koechling W, Plaksin D, Croston GE, Jeppesen J V, Macklon KT, Andersen CY. Comparative pharmacology of a new recombinant FSH expressed by a human cell line. Endocr Connect [Internet]. 2017;6:297\u2013305. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28450423. Accessed 1 Mar 2024.","DOI":"10.1530\/EC-17-0067"},{"key":"3146_CR16","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1002\/jcph.328","volume":"54","author":"H Olsson","year":"2014","unstructured":"Olsson H, Sandstr\u00f6m R, Grundemar L. Different pharmacokinetic and pharmacodynamic properties of recombinant follicle-stimulating hormone (rFSH) derived from a human cell line compared with rFSH from a non-human cell line. J Clin Pharmacol [Internet]. 2014;54:1299\u2013307. https:\/\/doi.org\/10.1002\/jcph.328.","journal-title":"J Clin Pharmacol [Internet]"},{"key":"3146_CR17","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1093\/humupd\/2.2.172","volume":"2","author":"CM Howles","year":"1996","unstructured":"Howles CM. Genetic engineering of human FSH (Gonal-F\u00ae). Hum Reprod Update [Internet]. 1996;2:172\u201391. https:\/\/doi.org\/10.1093\/humupd\/2.2.172.","journal-title":"Hum Reprod Update [Internet]"},{"key":"3146_CR18","unstructured":"Arce J-C, Klein BM, Erichsen L. Using AMH for determining a stratified gonadotropin dosing regimen for IVF\/ICSI and optimizing outcomes. In: Seifer DB, Tal R, editors. Anti-M\u00fcllerian hormone: biology, role in ovarian function and clinical significance. 1st ed. Nova Science Publishers, Inc; 2016. pp. 83\u2013102."},{"key":"3146_CR19","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1111\/cen.12864","volume":"83","author":"E Bosch","year":"2015","unstructured":"Bosch E, Nyboe Andersen A, Barri P, Garc\u00eda-Velasco JA, de Sutter P, Fern\u00e1ndez-S\u00e1nchez M, et al. Follicular and endocrine dose responses according to anti-M\u00fcllerian hormone levels in IVF patients treated with a novel human recombinant FSH (FE 999049). Clin Endocrinol (Oxf) [Internet]. 2015;83:902\u201312. https:\/\/doi.org\/10.1111\/cen.12864.","journal-title":"Clin Endocrinol (Oxf) [Internet]"},{"key":"3146_CR20","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s40268-016-0126-z","volume":"16","author":"TH Rose","year":"2016","unstructured":"Rose TH, R\u00f6shammar D, Erichsen L, Grundemar L, Ottesen JT. Characterisation of Population Pharmacokinetics and Endogenous Follicle-Stimulating Hormone (FSH) Levels After Multiple Dosing of a Recombinant Human FSH (FE 999049) in Healthy Women. Drugs R D [Internet]. 2016;16:165\u201372. https:\/\/doi.org\/10.1007\/s40268-016-0126-z.","journal-title":"Drugs R D [Internet]"},{"key":"3146_CR21","doi-asserted-by":"publisher","first-page":"136","DOI":"10.3390\/ph13070136","volume":"13","author":"L Bergandi","year":"2020","unstructured":"Bergandi L, Canosa S, Carosso AR, Paschero C, Gennarelli G, Silvagno F, et al. Human recombinant FSH and its biosimilars: clinical efficacy, safety, and cost-effectiveness in controlled ovarian stimulation for in vitro fertilization. Pharmaceuticals (Basel). 2020;13:136.","journal-title":"Pharmaceuticals (Basel)"},{"key":"3146_CR22","doi-asserted-by":"publisher","first-page":"57","DOI":"10.4103\/2229-3485.71852","volume":"1","author":"V Suvarna","year":"2010","unstructured":"Suvarna V. Phase IV of drug development. Perspect Clin Res. 2010;1:57\u201360.","journal-title":"Perspect Clin Res"},{"key":"3146_CR23","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ [Internet]. 2021;372:n71. http:\/\/www.bmj.com\/content\/372\/bmj.n71.abstract. Accessed 4 Mar 2024.","DOI":"10.1136\/bmj.n71"},{"key":"3146_CR24","first-page":"338","volume":"22","author":"ME Falagas","year":"2008","unstructured":"Falagas ME, Pitsouni EI, Malietzis GA, Pappas G. Comparison of PubMed, Scopus, Web of Science, and Google Scholar: strengths and weaknesses. FASEB J Off Publ Fed Am Soc Exp Biol. 2008;22:338\u201342.","journal-title":"FASEB J Off Publ Fed Am Soc Exp Biol"},{"key":"3146_CR25","doi-asserted-by":"crossref","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ [Internet]. 2019;366:l4898. http:\/\/www.bmj.com\/content\/366\/bmj.l4898.abstract. Accessed 4 Mar 2024.","DOI":"10.1136\/bmj.l4898"},{"key":"3146_CR26","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1411","volume":"12","author":"LA McGuinness","year":"2020","unstructured":"McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods [Internet]. 2020;12:55\u201361. https:\/\/doi.org\/10.1002\/jrsm.1411.","journal-title":"Res Synth Methods [Internet]"},{"key":"3146_CR27","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.fertnstert.2016.10.033","volume":"107","author":"A Nyboe Andersen","year":"2017","unstructured":"Nyboe Andersen A, Nelson SM, Fauser BCJM, Garc\u00eda-Velasco JA, Klein BM, Arce J-C, et al. Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial. Fertil Steril [Internet]. 2017;107:387-396.e4. https:\/\/doi.org\/10.1016\/j.fertnstert.2016.10.033.","journal-title":"Fertil Steril [Internet]"},{"key":"3146_CR28","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1016\/j.fertnstert.2020.10.059","volume":"115","author":"O Ishihara","year":"2021","unstructured":"Ishihara O, Klein BM, Arce J-C, Kuramoto T, Yokota Y, Mukaida T, et al. Randomized, assessor-blind, antim\u00fcllerian hormone-stratified, dose-response trial in Japanese in vitro fertilization\/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta. Fertil Steril [Internet]. 2021;115:1478\u201386. https:\/\/doi.org\/10.1016\/j.fertnstert.2020.10.059.","journal-title":"Fertil Steril [Internet]"},{"key":"3146_CR29","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1093\/humrep\/deab155","volume":"36","author":"J Qiao","year":"2021","unstructured":"Qiao J, Zhang Y, Liang X, Ho T, Huang H-Y, Kim S-H, et al. A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF\/ICSI patients. Hum Reprod [Internet]. 2021;36:2452\u201362. https:\/\/doi.org\/10.1093\/humrep\/deab155.","journal-title":"Hum Reprod [Internet]"},{"key":"3146_CR30","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.rbmo.2021.01.023","volume":"42","author":"O Ishihara","year":"2021","unstructured":"Ishihara O, Arce J-C. Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF\/ICSI patients: a randomized controlled trial. Reprod Biomed Online [Internet]. 2021;42:909\u201318. https:\/\/doi.org\/10.1016\/j.rbmo.2021.01.023.","journal-title":"Reprod Biomed Online [Internet]"},{"key":"3146_CR31","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1093\/humrep\/deac061","volume":"37","author":"M Fern\u00e1ndez S\u00e1nchez","year":"2022","unstructured":"Fern\u00e1ndez S\u00e1nchez M, Vi\u0161nov\u00e1 H, Larsson P, Yding Andersen C, Filicori M, Blockeel C, et al. A randomized, controlled, first-in-patient trial of choriogonadotropin beta added to follitropin delta in women undergoing ovarian stimulation in a long GnRH agonist protocol. Hum Reprod [Internet]. 2022;37:1161\u201374. https:\/\/doi.org\/10.1093\/humrep\/deac061.","journal-title":"Hum Reprod [Internet]"},{"key":"3146_CR32","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s12958-022-01016-y","volume":"20","author":"R Yang","year":"2022","unstructured":"Yang R, Zhang Y, Liang X, Song X, Wei Z, Liu J, et al. Comparative clinical outcome following individualized follitropin delta dosing in Chinese women undergoing ovarian stimulation for in vitro fertilization \/intracytoplasmic sperm injection. Reprod Biol Endocrinol. 2022;20:147.","journal-title":"Reprod Biol Endocrinol"},{"key":"3146_CR33","doi-asserted-by":"crossref","unstructured":"Arce J-C, Larsson P, Garc\u00eda-Velasco JA. Establishing the follitropin delta dose that provides a comparable ovarian response to 150 IU\/day follitropin alfa. Reprod Biomed Online [Internet]. 2020;41:616\u201322. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1472648320303771. Accessed 1 Mar 2024.","DOI":"10.1016\/j.rbmo.2020.07.006"},{"key":"3146_CR34","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s40261-022-01232-9","volume":"43","author":"F Shao","year":"2023","unstructured":"Shao F, Jiang Y, Ding S, Larsson P, Pinton P, Jonker DM. Pharmacokinetics and Safety of Follitropin Delta in Gonadotropin Down-Regulated Healthy Chinese Women. Clin Drug Investig. 2023;43:37\u201344.","journal-title":"Clin Drug Investig"},{"key":"3146_CR35","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.rbmo.2018.10.012","volume":"38","author":"E Bosch","year":"2019","unstructured":"Bosch E, Havelock J, Martin FS, Rasmussen BB, Klein BM, Mannaerts B, et al. Follitropin delta in repeated ovarian stimulation for IVF: a controlled, assessor-blind Phase 3 safety trial. Reprod Biomed Online [Internet]. 2019;38:195\u2013205. https:\/\/doi.org\/10.1016\/j.rbmo.2018.10.012.","journal-title":"Reprod Biomed Online [Internet]"},{"key":"3146_CR36","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.rbmo.2021.08.024","volume":"43","author":"H Vi\u0161nov\u00e1","year":"2021","unstructured":"Vi\u0161nov\u00e1 H, Papaleo E, Martin FS, Koziol K, Klein BM, Mannaerts B. Clinical outcomes of potential high responders after individualized FSH dosing based on anti-M\u00fcllerian hormone and body weight. Reprod Biomed Online [Internet]. 2021;43:1019\u201326. https:\/\/doi.org\/10.1016\/j.rbmo.2021.08.024.","journal-title":"Reprod Biomed Online [Internet]"},{"key":"3146_CR37","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.rbmo.2021.09.014","volume":"44","author":"O Ishihara","year":"2022","unstructured":"Ishihara O, Nelson SM, Arce J-C. Comparison of ovarian response to follitropin delta in Japanese and White IVF\/ICSI patients. Reprod Biomed Online [Internet]. 2022;44:177\u201384. https:\/\/doi.org\/10.1016\/j.rbmo.2021.09.014.","journal-title":"Reprod Biomed Online [Internet]"},{"key":"3146_CR38","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ejogrb.2023.12.011","volume":"293","author":"G Porcu-Buisson","year":"2024","unstructured":"Porcu-Buisson G, Maignien C, Swierkowski-Blanchard N, Rongi\u00e8res C, Ranisavljevic N, Oger P, et al. Prospective multicenter observational real-world study to assess the use, efficacy and safety profile of follitropin delta during IVF\/ICSI procedures (DELTA Study). Eur J Obstet Gynecol Reprod Biol. 2024;293:21\u20136.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"3146_CR39","doi-asserted-by":"publisher","first-page":"992677","DOI":"10.3389\/fendo.2022.992677","volume":"13","author":"C Blockeel","year":"2022","unstructured":"Blockeel C, Griesinger G, Rago R, Larsson P, Sonderegger YLY, Rivi\u00e8re S, et al. Prospective multicenter non-interventional real-world study to assess the patterns of use, effectiveness and safety of follitropin delta in routine clinical practice (the PROFILE study). Front Endocrinol (Lausanne). 2022;13:992677.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"3146_CR40","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.rbmo.2021.12.013","volume":"44","author":"A Bachmann","year":"2022","unstructured":"Bachmann A, Kissler S, Laubert I, Mehrle P, Mempel A, Reissmann C, et al. An eight centre, retrospective, clinical practice data analysis of algorithm-based treatment with follitropin delta. Reprod Biomed Online [Internet]. 2022;44:853\u20137. https:\/\/doi.org\/10.1016\/j.rbmo.2021.12.013.","journal-title":"Reprod Biomed Online [Internet]"},{"key":"3146_CR41","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ejogrb.2022.11.006","volume":"280","author":"P Kovacs","year":"2023","unstructured":"Kovacs P, Jayakumaran J, Lu Y, Lindheim SR. Comparing pregnancy rates following ovarian stimulation with follitropin-\u0394 to follitropin -\u03b1 in routine IVF: A retrospective analysis. Eur J Obstet Gynecol Reprod Biol [Internet]. 2023;280:22\u20137. https:\/\/doi.org\/10.1016\/j.ejogrb.2022.11.006.","journal-title":"Eur J Obstet Gynecol Reprod Biol [Internet]"},{"key":"3146_CR42","doi-asserted-by":"publisher","unstructured":"Havelock J, Aaris Henningsen A-K, Mannaerts B, Arce J-C, Groups E-1 and E-2 T. Pregnancy and neonatal outcomes in fresh and frozen cycles using blastocysts derived from ovarian stimulation with follitropin delta. J Assist Reprod Genet [Internet]. 2021;38:2651\u201361. https:\/\/doi.org\/10.1007\/s10815-021-02271-5","DOI":"10.1007\/s10815-021-02271-5"},{"key":"3146_CR43","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.rbmo.2018.12.032","volume":"38","author":"M Fern\u00e1ndez-S\u00e1nchez","year":"2019","unstructured":"Fern\u00e1ndez-S\u00e1nchez M, Visnova H, Yuzpe A, Klein BM, Mannaerts B, Arce J-C. Individualization of the starting dose of follitropin delta reduces the overall OHSS risk and\/or the need for additional preventive interventions: cumulative data over three stimulation cycles. Reprod Biomed Online [Internet]. 2019;38:528\u201337. https:\/\/doi.org\/10.1016\/j.rbmo.2018.12.032.","journal-title":"Reprod Biomed Online [Internet]"},{"key":"3146_CR44","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s40261-015-0276-8","volume":"35","author":"H Olsson","year":"2015","unstructured":"Olsson H, Sandstr\u00f6m R, Bagger Y. Dose-exposure proportionality of a novel recombinant follicle-stimulating hormone (rFSH), FE 999049, derived from a human cell line, with comparison between Caucasian and Japanese women after subcutaneous administration. Clin Drug Investig [Internet]. 2015;35:247\u201353. https:\/\/doi.org\/10.1007\/s40261-015-0276-8.","journal-title":"Clin Drug Investig [Internet]"},{"key":"3146_CR45","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.rbmo.2021.08.024","volume":"43","author":"H Vi\u0161nov\u00e1","year":"2021","unstructured":"Vi\u0161nov\u00e1 H, Papaleo E, Martin FS, Koziol K, Klein BM, Mannaerts B. Clinical outcomes of potential high responders after individualized FSH dosing based on anti-M\u00fcllerian hormone and body weight. Reprod Biomed Online. 2021;43:1019\u201326.","journal-title":"Reprod Biomed Online"},{"key":"3146_CR46","doi-asserted-by":"publisher","first-page":"379","DOI":"10.3390\/medicina57040379","volume":"57","author":"B Doroftei","year":"2021","unstructured":"Doroftei B, Ilie O-D, Dabuleanu A-M, Diaconu R, Maftei R, Simionescu G, et al. Follitropin delta as a state-of-the-art incorporated companion for assisted reproductive procedures: A two year observational study. Medicina. 2021;57:379.","journal-title":"Medicina"},{"key":"3146_CR47","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.fertnstert.2020.09.158","volume":"115","author":"F Bissonnette","year":"2021","unstructured":"Bissonnette F, MinanoMasip J, Kadoch I-J, Librach C, Sampalis J, Yuzpe A. Individualized ovarian stimulation for in vitro fertilization: a multicenter, open label, exploratory study with a mixed protocol of follitropin delta and highly purified human menopausal gonadotropin. Fertil Steril [Internet]. 2021;115:991\u20131000. https:\/\/doi.org\/10.1016\/j.fertnstert.2020.09.158.","journal-title":"Fertil Steril [Internet]"},{"key":"3146_CR48","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1111\/cen.13956","volume":"90","author":"SM Nelson","year":"2019","unstructured":"Nelson SM, Larsson P, Mannaerts BMJL, Nyboe Andersen A, Fauser BCJM. Anti-M\u00fcllerian hormone variability and its implications for the number of oocytes retrieved following individualized dosing with follitropin delta. Clin Endocrinol (Oxf) [Internet]. 2019;90:719\u201326. https:\/\/doi.org\/10.1111\/cen.13956.","journal-title":"Clin Endocrinol (Oxf) [Internet]"},{"key":"3146_CR49","doi-asserted-by":"crossref","unstructured":"Bungum L, Tagevi J, Jokubkiene L, Bungum M, Giwercman A, Macklon N, et al. The impact of the biological variability or assay performance on amh measurements: A prospective cohort study with AMH tested on three analytical assay-platforms. Front Endocrinol (Lausanne) [Internet]. 2018;9:603. https:\/\/pubmed.ncbi.nlm.nih.gov\/30459709. Accessed 1 Mar 2024.","DOI":"10.3389\/fendo.2018.00603"},{"key":"3146_CR50","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1055\/a-0840-3817","volume":"79","author":"U Gorkem","year":"2019","unstructured":"Gorkem U, Togrul C. Is There a Need to Alter the Timing of Anti-M\u00fcllerian Hormone Measurement During the Menstrual Cycle? Geburtshilfe Frauenheilkd. 2019;79:731\u20137.","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"3146_CR51","doi-asserted-by":"publisher","first-page":"686","DOI":"10.3389\/fendo.2018.00686","volume":"9","author":"L Melado","year":"2018","unstructured":"Melado L, Lawrenz B, Sibal J, Abu E, Coughlan C, Navarro AT, et al. Anti-m\u00fcllerian Hormone During Natural Cycle Presents Significant Intra and Intercycle Variations When Measured With Fully Automated Assay. Front Endocrinol (Lausanne). 2018;9:686.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"3146_CR52","doi-asserted-by":"crossref","unstructured":"Iliodromiti S, Salje B, Dewailly D, Fairburn C, Fanchin R, Fleming R, et al. Non-equivalence of anti-M\u00fcllerian hormone automated assays-clinical implications for use as a companion diagnostic for individualised gonadotrophin dosing. Hum Reprod [Internet]. 2017;32:1710\u20135. https:\/\/pubmed.ncbi.nlm.nih.gov\/28854583. Accessed 1 Mar 2024.","DOI":"10.1093\/humrep\/dex219"},{"key":"3146_CR53","doi-asserted-by":"publisher","first-page":"hox026","DOI":"10.1093\/hropen\/hox026","volume":"2017","author":"\u00c5 Magnusson","year":"2017","unstructured":"Magnusson \u00c5, Oler\u00f6d G, Thurin-Kjellberg A, Bergh C. The correlation between AMH assays differs depending on actual AMH levels. Hum Reprod Open. 2017;2017:hox026.","journal-title":"Hum Reprod Open"},{"key":"3146_CR54","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1097\/AOG.0000000000003163","volume":"133","author":"ACOG Committee Opinion No","year":"2019","unstructured":"ACOG Committee Opinion No. 773 Summary: The Use of Antim\u00fcllerian Hormone in Women Not Seeking Fertility Care. Obstet Gynecol. 2019;133:840\u20131.","journal-title":"Obstet Gynecol"},{"key":"3146_CR55","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1080\/09513590.2020.1810659","volume":"37","author":"A La Marca","year":"2021","unstructured":"La Marca A, Tolani AD, Capuzzo M. The interchangeability of two assays for the measurement of anti-M\u00fcllerian hormone when personalizing the dose of FSH in in-vitro fertilization cycles. Gynecol Endocrinol Off J Int Soc Gynecol Endocrinol. 2021;37:372\u20136.","journal-title":"Gynecol Endocrinol Off J Int Soc Gynecol Endocrinol"},{"key":"3146_CR56","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.xfre.2020.12.002","volume":"2","author":"O Haakman","year":"2021","unstructured":"Haakman O, Liang T, Murray K, Vilos A, Vilos G, Bates C, et al. In vitro fertilization cycles stimulated with follitropin delta result in similar embryo development and quality when compared with cycles stimulated with follitropin alfa or follitropin beta. F&S Reports [Internet]. 2021;2:30\u20135. https:\/\/doi.org\/10.1016\/j.xfre.2020.12.002.","journal-title":"F&S Reports [Internet]"},{"key":"3146_CR57","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12958-023-01090-w","volume":"21","author":"MF S\u00e1nchez","year":"2023","unstructured":"S\u00e1nchez MF, Larsson P, Serrano MF, Bosch E, Velasco JAG, L\u00f3pez ES, et al. Live birth rates following individualized dosing algorithm of follitropin delta in a long GnRH agonist protocol. Reprod Biol Endocrinol. 2023;21:45.","journal-title":"Reprod Biol Endocrinol"},{"key":"3146_CR58","doi-asserted-by":"crossref","unstructured":"Gazzo I, Bovis F, Colia D, Sozzi F, Costa M, Anserini P, et al. Algorithm vs clinical experience: controlled ovarian stimulations with follitropin delta and individualised doses of follitropin alpha\/beta. Reprod Fertil [Internet]. 2024;5:e230045. https:\/\/raf.bioscientifica.com\/view\/journals\/raf\/5\/1\/RAF-23-0045.xml. Accessed 29 Feb 2024.","DOI":"10.1530\/RAF-23-0045"},{"key":"3146_CR59","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13048-022-01079-w","volume":"16","author":"S Arab","year":"2023","unstructured":"Arab S, Frank R, Ruiter J, Dahan MH. How to dose follitropin delta for the first insemination cycle according to the ESHRE and ASRM guidelines; a retrospective cohort study. J Ovarian Res [Internet]. 2023;16:24. https:\/\/doi.org\/10.1186\/s13048-022-01079-w.","journal-title":"J Ovarian Res [Internet]"},{"key":"3146_CR60","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13048-021-00773-5","volume":"14","author":"S Yacoub","year":"2021","unstructured":"Yacoub S, Cadesky K, Casper RF. Low risk of OHSS with follitropin delta use in women with different polycystic ovary syndrome phenotypes: a retrospective case series. J Ovarian Res [Internet]. 2021;14:31. https:\/\/doi.org\/10.1186\/s13048-021-00773-5.","journal-title":"J Ovarian Res [Internet]"},{"key":"3146_CR61","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12958-023-01172-9","volume":"22","author":"OB Duarte-Filho","year":"2024","unstructured":"Duarte-Filho OB, Miyadahira EH, Matsumoto L, Yamakami LYS, Tomioka RB, Podgaec S. Follitropin delta combined with menotropin in patients at risk for poor ovarian response during in vitro fertilization cycles: a prospective controlled clinical study. Reprod Biol Endocrinol. 2024;22:7.","journal-title":"Reprod Biol Endocrinol"},{"key":"3146_CR62","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1080\/17425247.2019.1651290","volume":"16","author":"S Longobardi","year":"2019","unstructured":"Longobardi S, Seidler A, Martins J, Beckers F, MacGillivray W, D\u2019Hooghe T. An evaluation of the use and handling errors of currently available recombinant human follicle-stimulating hormone pen injectors by women with infertility and fertility nurses. Expert Opin Drug Deliv [Internet]. 2019;16:1003\u201314. https:\/\/doi.org\/10.1080\/17425247.2019.1651290.","journal-title":"Expert Opin Drug Deliv [Internet]"},{"key":"3146_CR63","doi-asserted-by":"crossref","unstructured":"Baldini GM, Mastrorocco A, Sciorio R, Palini S, Dellino M, Cascardi E, et al. Inadvertent administration of 72 \u00b5g of Follitropin-\u0394 for three consecutive days does not appear to be dangerous for poor responders: a case series. J Clin Med. 2023;12:5202.","DOI":"10.3390\/jcm12165202"}],"container-title":["Journal of Assisted Reproduction and Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10815-024-03146-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10815-024-03146-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10815-024-03146-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T11:18:01Z","timestamp":1721647081000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10815-024-03146-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,29]]},"references-count":63,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["3146"],"URL":"https:\/\/doi.org\/10.1007\/s10815-024-03146-1","relation":{},"ISSN":["1058-0468","1573-7330"],"issn-type":[{"value":"1058-0468","type":"print"},{"value":"1573-7330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,29]]},"assertion":[{"value":"13 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}